A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

This study is evaluating the safety of teclistamab (a bispecific antibody that targets multiple myeloma cells) specifically in Indian patients with multiple myeloma that has relapsed (come back) or stopped responding to prior treatments. **You may be eligible if:** - You have multiple myeloma that has relapsed or become resistant to treatment - You have received at least 3 prior lines of therapy, including a proteasome inhibitor, an anti-CD38 antibody (such as daratumumab), and an immunomodulatory drug (such as lenalidomide) - Your disease is currently progressing - You are in reasonably good physical health - You are willing to use effective contraception **You may NOT be eligible if:** - You have active, uncontrolled infection - You have significant organ damage - You are pregnant or breastfeeding - You have had certain prior treatments that would interact with teclistamab Talk to your doctor to see if this trial is right for you.